Papers matching “adjuvant chemotherapy response” 54
Not finding it? Sign in to also search OpenAlex live.
-
P14.41 Cost-effectiveness of FET PET for early treatment response assessment in glioma patients following adjuvant temozolomide chemotherapy2021 Neuro-Oncology conference-abstract Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access
Jurij Rosen, Garry S. Ceccon, E K Bauer, Jan‐Michael Werner, Christoph Kabbasch, Gereon R. Fink, +2 more
0citations -
Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02)2026 The Breast article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Mark Opdam, N. Ultee, Jill J.J. Geenen, Annelot G.J. van Rossum, Ingrid A.M. Mandjes, Sara Balduzzi, +5 more
0citations -
CRITICS-II: A multicenter randomized phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.2026 Journal of Clinical Oncology conference-abstract Medicine Gastric Cancer Management and Outcomes Open access
Marcel Verheij, Nicole C.T. van Grieken, Astrid E. Slagter, Romy M. van Amelsfoort, Shermarke Hassan, Evelien Schouten, +15 more
3citations -
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Monika Graeser, Felix Hilpert, Katja Krauss, +11 more
18citations -
Author response to: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma2022 British journal of surgery peer-review Medicine Gastric Cancer Management and Outcomes Open access
Arnaldo N. S. Silva, Yuichi Saito, Takaki Yoshikawa, Takashi Oshima, Jeremy David Hayden, Jan Oosting, +11 more
0citations -
The Risk of Distant Metastases in Patients With Clinical Complete Response Managed by Watch and Wait After Neoadjuvant Therapy for Rectal Cancer: The Influence of Local Regrowth in the International Watch and Wait Database2022 Diseases of the Colon & Rectum article Medicine Colorectal Cancer Surgical Treatments Open access
Laura Melina Fernandez, Guilherme Pagin São Julião, Andrew G. Renehan, Geerard L. Beets, Ana Luísa Papoila, Bruna Borba Vailati, +7 more
94citations -
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer2024 npj Breast Cancer article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Volker J. Möbus, Hans‐Joachim Lück, Ekkehart Ladda, Peter Klare, Knut Engels, Marcus Schmidt, +20 more
2citations -
Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial2021 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Nadia Harbeck, Oleg Gluz, Sherko Küemmel, Matthias Christgen, Michael S Braun, Bahriye Aktas, +21 more
12citations -
MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study
Fleur M. Louis, Anna van der Voort, Mette S. van Ramshorst, Antonios Daletzakis, Ingrid A.M. Mandjes, Inge Kemper, +49 more
8citations -
Response to the letter to the editor by Pontoriero et al. regarding the article “Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer – PORTEC-4a an international randomised phase 3 trial by Van den Heerik et al.”
Anne Sophie V M van den Heerik, Nanda Horeweg, Carien L. Creutzberg, Wilbert B. van den Hout
0citations -
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer2023 Journal of Clinical Oncology article Medicine Endometrial and Cervical Cancer Treatments Open access
Nanda Horeweg, Remi A. Nout, Ina Maria Jurgenliemk-Schulz, Ludy C.H.W. Lutgens, Jan J. Jobsen, Marie A.D. Haverkort, +38 more
104citations -
Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer2022 Journal for ImmunoTherapy of Cancer article Immunology and Microbiology Immunotherapy and Immune Responses Open access cited by 2 patents
Marit Martina Melssen, Caroline T. Fisher, Craig Lee Slingluff, Cornelis J.M. Melief
42citations -
Clinical relevance of CA125 in low-grade serous ovarian cancer: a retrospective multi-center JAGO/NOGGO study2026 International Journal of Gynecological Cancer article Medicine Ovarian cancer diagnosis and treatment Open access
Chiara Flethe, Mina Netkova-Heintzen, Magdalena Postl, L. Tascón Padrón, Christina Victoria Isabella Tauber, Elisa Sieghartsleitner, +7 more
0citations